ALLARITY Full Color RGB 2023JUN07.png
Allarity Therapeutics’ Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer
June 25, 2024 08:00 ET | Allarity Therapeutics, Inc.
Multiple patients have now exceeded 30 weeks on treatment Boston (June 25, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical...
ALLARITY Full Color RGB 2023JUN07.png
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer
March 27, 2024 08:30 ET | Allarity Therapeutics, Inc.
  The stenoparib Phase 2 monotherapy trial in advanced, recurrent ovarian cancer continues to show promise, prompting shift in resources to accelerate stenoparib development Further development of...
ALLARITY Full Color RGB 2023JUN07.png
Allarity’s Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP® Companion Diagnostic
December 05, 2023 07:30 ET | Allarity Therapeutics, Inc.
All evaluable participants, with prior PARP inhibitor therapy and chemotherapy, showed significant tumor shrinkage including one complete response Early data follows Phase 2 dose optimization...
ALLARITY Full Color RGB 2023JUN07.png
PLOS ONE Publishes Data on Allarity Therapeutics’ DRP® Companion Diagnostic for Dovitinib
August 30, 2023 16:05 ET | Allarity Therapeutics, Inc.
- The DRP®-Dovitinib companion diagnostic demonstrated an ability to identify advanced renal cell carcinoma patients that have improved clinical benefit from dovitinib treatment, as compared to...
Allarity Therapeutics and FivepHusion Announce Collaboration to Support Clinical Development of Deflexifol™ with DRP® Companion Diagnostics
July 31, 2023 06:00 ET | Allarity Therapeutics, Inc.
                                                                         BOSTON and SYDNEY (July 31, 2023) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity”), a clinical-stage...
Processa Pharmaceuticals Announces Prioritization on Development of Next Generation Chemotherapies
February 21, 2023 08:30 ET | Processa Pharmaceuticals, Inc.
Our Next Generation Chemotherapies (NGCs) are cancer treatments where the metabolism and/or distribution of an FDA-approved drug has been altered to provide potentially safer and more effective...
Straits Research Pvt Ltd
Oncology Biosimilar Market Size is projected to reach USD 15.62 billion by 2031, growing at a CAGR of 20.5%: Straits Research
November 23, 2022 10:25 ET | Straits Research
New York, United States, Nov. 23, 2022 (GLOBE NEWSWIRE) -- A biosimilar is a generic version of a well-known biologic drug. Biologic drugs are medicines made from living things like cells, tissues,...
BriaCell Anti-Cancer Technology Published in Leading Cancer Drug Discovery Journal
June 24, 2022 09:00 ET | BriaCell Therapeutics Corp.
Anti-Cancer activity of BriaCell’s lead candidate, Bria-IMT™, in advanced breast cancer patients was published in a leading peer-reviewed publication. Bria-IMT™, through a novel mechanism of action,...
Allarity Therapeutics Provides Update on Dovitinib Program
March 15, 2022 08:32 ET | Allarity Therapeutics, Inc.
FOR IMMEDIATE RELEASE Allarity has requested a Type C meeting with the FDA to discuss potential clinical paths to support approval of dovitinib in view of the regulatory agency’s recent Refusal to...
Celsion Corporation Appoints Dr. Stacy R. Lindborg to its Board of Directors
June 08, 2021 08:00 ET | Celsion CORP
25-year pharmaceutical industry executive brings broad drug development perspective Replaces Alberto Martinez, MD LAWRENCEVILLE, N.J., June 08, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation...